Cell Source

Company Overview

Snapshot

Founded in September 2011, Cell Source operates with 11–50 employees. The company has raised $21.54 million across one funding round from its public offering. In May 2014, Cell Source went public on the OTC market.

Business overview

Cell Source is a biotechnology company focused on developing cell therapy treatments that manage immune tolerance. The company's core technology, the patented Veto Cell platform, processes white blood cells using a proprietary mix of FDA-approved cytokines to activate their inherent attacker-blocking capabilities. These Veto Cells can then be reintroduced into the body to facilitate bone marrow and organ transplantation, and to treat blood cancers like lymphoma and congenital diseases such as sickle cell anemia. Cell Source operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals and Biotechnology markets in the United States.

Strategic signal

In May 2026, Cell Source presented breakthrough developments for mismatched donor stem cell and organ transplants, and off-the-shelf CAR-T cell therapy at the LD Micro Invitational Conference. This highlights the company's ongoing innovation and potential to significantly impact critical areas of cell therapy, signaling continued progress in its clinical development and strategic positioning within the biotechnology landscape.

Company Intelligence Q&A

What is Cell Source's primary focus?

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance, utilizing its patented Veto Cell technology.

When did Cell Source go public?

Cell Source went public on the OTC market in May 2014.

What was the total capital raised by Cell Source?

Cell Source has raised a total of $21.54 million through its public offering.

What recent developments did Cell Source present?

In May 2026, Cell Source presented breakthrough developments for mismatched donor stem cell and organ transplants and off-the-shelf CAR-T cell therapy at the LD Micro Invitational Conference in Los Angeles.

What was the key finding from Cell Source's Veto Cell clinical trial?

In November 2024, Cell Source shared promising interim results from its groundbreaking Veto Cell clinical trial.